MARKET

IRWD

IRWD

Ironwood
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.52
-0.07
-0.60%
After Hours: 11.27 -0.25 -2.17% 16:22 05/16 EDT
OPEN
11.25
PREV CLOSE
11.59
HIGH
11.70
LOW
11.00
VOLUME
1.25M
TURNOVER
0
52 WEEK HIGH
14.27
52 WEEK LOW
10.13
MARKET CAP
1.77B
P/E (TTM)
3.570
1D
5D
1M
3M
1Y
5Y
Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data at Digestive Disease Week® 2022
BOSTON, May 09, 2022--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that the company and its collaborators will present eight studies, including two oral presentations, during the Digestive Disease Week® (D...
Business Wire · 05/09 12:00
Ironwood (IRWD) Q1 Earnings Miss, Linzess Growth Continues
Ironwood (IRWD) witnesses strong year-over-year sales growth on continued demand for Linzess. Its first-quarter earnings miss estimates. The company maintains revenue guidance for 2022. Stock declines.
Zacks · 05/06 14:24
Ironwood Pharmaceuticals: Q1 Earnings Insights
  Ironwood Pharmaceuticals (NASDAQ:IRWD) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/05 13:13
Ironwood Pharmaceuticals (IRWD) Q1 Earnings Miss Estimates
Ironwood (IRWD) delivered earnings and revenue surprises of -22.22% and 2.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 12:45
Ironwood Pharmaceuticals Q1 EPS $0.21 Misses $0.25 Estimate, Sales $97.53M Beat $94.35M Estimate
Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly earnings of $0.21 per share which missed the analyst consensus estimate of $0.25 by 16 percent. This is a 12.5 percent decrease over earnings of $0.24 per share
Benzinga · 05/05 11:11
BRIEF-Ironwood Pharmaceuticals Reports First Quarter 2022 Results
reuters.com · 05/05 11:09
Ironwood Pharmaceuticals Non-GAAP EPS of $0.21, revenue of $98M
Ironwood Pharmaceuticals press release (NASDAQ:IRWD): Q1 Non-GAAP EPS of $0.21. Revenue of $98M. FY22 financial guidance maintained.
Seekingalpha · 05/05 11:03
-- Earnings Flash (IRWD) IRONWOOD PHARMACEUTICALS Posts Q1 Revenue $97.5M
MT Newswires · 05/05 07:17
More
No Data
Learn about the latest financial forecast of IRWD. Analyze the recent business situations of Ironwood through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

16.67%Strong Buy
33.33%Buy
50.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average IRWD stock price target is 13.00 with a high estimate of 16.00 and a low estimate of 9.00.
High16.00
Average13.00
Low9.00
Current 11.52
EPS
Actual
Estimate
0.090.180.260.35
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 304
Institutional Holdings: 185.24M
% Owned: 120.41%
Shares Outstanding: 153.84M
TypeInstitutionsShares
Increased
70
8.20M
New
30
2.73M
Decreased
79
14.17M
Sold Out
42
2.12M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.23%
Pharmaceuticals & Medical Research
+1.02%
Key Executives
Non-Executive Chairman/Independent Director
Julie Mchugh
President/Chief Executive Officer/Director
Thomas McCourt
Chief Financial Officer/Senior Vice President
Sravan Emany
Chief Operating Officer/Senior Vice President
Jason Rickard
Senior Vice President/Secretary
John Minardo
Senior Vice President
Michael Shetzline
Chief Accounting Officer/Controller
Ronald Silver
Independent Director
Mark Currie
Independent Director
Alexander Denner
Independent Director
Andrew Dreyfus
Independent Director
Jon Duane
Independent Director
Marla Kessler
Independent Director
Catherine Moukheibir
Independent Director
Lawrence Olanoff
Independent Director
Edward Owens
Independent Director
Jay Shepard
No Data
No Data
About IRWD
Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).

Webull offers kinds of Ironwood Pharmaceuticals, Inc. stock information, including NASDAQ:IRWD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRWD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IRWD stock methods without spending real money on the virtual paper trading platform.